Ashton Thomas Private Wealth LLC Purchases New Shares in Halozyme Therapeutics, Inc. $HALO

Key Points

• Ashton Thomas Private Wealth LLC has acquired a new stake in Halozyme Therapeutics, buying 4,170 shares valued at roughly $266,000 during the first quarter of the year.
• The biopharmaceutical company reported a significant earnings beat, with $1.54 earnings per share (EPS) compared to a consensus estimate of $1.23, along with quarterly revenue of $325.72 million.
• Institutional investors own 97.79% of Halozyme's stock, indicating a high level of institutional interest and commitment to the company.

Ashton Thomas Private Wealth LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 4,170 shares of the biopharmaceutical company's stock, valued at approximately $266,000.

Several other large investors have also added to or reduced their stakes in the stock. Isthmus Partners LLC boosted its holdings in Halozyme Therapeutics by 2.5% in the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company's stock valued at $439,000 after acquiring an additional 169 shares in the last quarter. OneDigital Investment Advisors LLC boosted its holdings in Halozyme Therapeutics by 1.7% in the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company's stock valued at $649,000 after acquiring an additional 175 shares in the last quarter. Park Place Capital Corp boosted its holdings in shares of Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after buying an additional 182 shares in the last quarter. Xponance Inc. boosted its holdings in shares of Halozyme Therapeutics by 1.1% during the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company's stock valued at $1,190,000 after buying an additional 198 shares in the last quarter. Finally, Bessemer Group Inc. boosted its holdings in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $76.90 on Friday. The stock has a market cap of $8.99 billion, a price-to-earnings ratio of 17.60, a PEG ratio of 0.43 and a beta of 1.19. The firm's 50-day moving average is $65.11 and its 200 day moving average is $60.45. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $77.60. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. The business had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HALO. Wall Street Zen cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a report on Wednesday, August 6th. Morgan Stanley boosted their target price on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a report on Monday, August 18th. The Goldman Sachs Group began coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They set a "neutral" rating and a $55.00 target price on the stock. Finally, HC Wainwright boosted their target price on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $67.11.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 4,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the transaction, the director owned 46,952 shares in the company, valued at approximately $3,459,423.36. This represents a 7.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Nicole Labrosse sold 20,000 shares of the company's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the transaction, the chief financial officer owned 24,306 shares in the company, valued at $1,840,207.26. This represents a 45.14% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 124,000 shares of company stock worth $7,830,320. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.